Director granted Caris Life Sciences (CAI) stock for 2025 board fees

Rhea-AI Filing Summary

Caris Life Sciences director Jeff L. Vacirca received a stock grant instead of cash board fees. On February 26, 2026, he acquired 2,492 shares of common stock at $20.06 per share as compensation for his 2025 board retainer, bringing his direct holdings to 18,621 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vacirca Jeff L

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TX 75039

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A(1)		2,492	A	$20.06	18,621	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Caris Life Sciences (CAI) report for Jeff L. Vacirca?

Caris Life Sciences reported that director Jeff L. Vacirca acquired 2,492 shares of common stock as a grant on February 26, 2026. The shares were issued as compensation for his 2025 board retainer fees instead of paying cash.

Was the Caris Life Sciences (CAI) Form 4 a stock purchase or a grant?

The Form 4 reports a stock grant, not an open-market purchase. Jeff L. Vacirca received 2,492 shares as a grant in lieu of cash for 2025 board retainer fees, based on a ten-day average trading price calculation.

What price was used to determine Jeff L. Vacirca’s Caris Life Sciences (CAI) share grant?

The number of shares was determined using the ten trading day average of the daily volume weighted average price per share through February 25, 2026. The Form 4 reflects a grant price of $20.06 per share for 2,492 common shares.

How many Caris Life Sciences (CAI) shares does Jeff L. Vacirca own after this transaction?

After receiving the 2,492-share grant, Jeff L. Vacirca directly owns 18,621 shares of Caris Life Sciences common stock. This figure includes the newly issued shares received as compensation for his 2025 board retainer fees.

Why did Caris Life Sciences (CAI) issue shares to Jeff L. Vacirca instead of paying cash?

The shares were issued in lieu of cash compensation for 2025 board retainer fees. The company calculated the share amount by dividing the earned cash retainer by a ten-day average volume weighted average price through February 25, 2026.